Jez Moulding has been appointed chief operating officer of UDG Healthcare and executive vice president of Ashfield, a division of UDG, effective 2 May 2017.

Moulding (pictured) will oversee the Ashfield division globally and, in his role as chief operating officer of UDG, will have responsibility for group IT, quality, compliance, strategy and communication.

Chief executive of UDG Healthcare Brendan McAtamney will continue to oversee the company’s Sharp and Aquilant divisions.

Chris Corbin will transition to the role of chairman of Ashfield and continue as a non-executive director of UDG Healthcare.

Moulding joins from Sanofi where he has worked for 18 years, most recently as senior vice president and North America region head for diabetes and cardiovascular, responsible for sales of over $5 billion.  Prior to joining Sanofi in 1999, Jez held a variety of positions at Astra Pharmaceuticals and Winchester Pharmaceuticals in the UK.

McAtamney commented: “We are delighted to welcome Jez to UDG Healthcare and to Ashfield. He has extensive leadership experience in the pharmaceutical sector within our key global markets. His most recent experience leading the Sanofi North American business will be extremely valuable to us as we continue to develop our Ashfield US business and expand the group internationally.”

Moulding said: “Ashfield has grown over many years and is a market leader in commercialisation services to global pharmaceutical clients. I look forward to building on this strong platform and driving further international expansion across the group.”